Nod-like receptors: Key molecular switches in the conundrum of cancer

Frontiers in Immunology

Volumn 5, Issue APR, 2014, Pages

  Kent, Andrew ^a   Blander, J Magarian ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Immunoediting; Immunosurveillance; Innate immunity; Nod like receptors; Transformation

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CD4 ANTIGEN; CD8 ANTIGEN; CRYOPYRIN; DNA; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; NOD LIKE RECEPTOR FAMILY CARD DOMAIN CONTAINING PROTEIN 4; NOD LIKE RECEPTOR FAMILY PYRIN DOMAIN CONTAINING 6; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PROTEIN; PURINERGIC RECEPTOR; STAT1 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 5; UNCLASSIFIED DRUG;

CHRONIC INFLAMMATION; DENDRITIC CELL; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; IMMUNOSURVEILLANCE; INNATE IMMUNITY; METASTASIS; NEOPLASM; NONHUMAN; ONCOGENESIS AND MALIGNANT TRANSFORMATION; PHAGOCYTE; SHORT SURVEY; SIGNAL TRANSDUCTION; TISSUE REPAIR; TUMOR IMMUNOLOGY;

EID: 84900845431     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00185     Document Type: Short Survey

References (57)

1. Martin E. Toward and anthropology of immunology: the body as nation state. Med Anthropol Q (1990) 4:17. doi:10.1525/maq.1990.4.4.02a00030.
2. Tauber AI. Metchnikoff and the phagocytosis theory. Nat Rev Mol Cell Biol (2003) 4:897-901. doi:10.1038/nrm1244.
3. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature (2008) 454:436-44. doi:10.1038/nature07205.
4. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell (2010) 140:883-99. doi:10.1016/j.cell.2010.01.025.
5. Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Med (Zagreb) (2011) 21:264-75. doi:10.11613/BM.2011.036.
6. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 6:24-37. doi:10.1038/nrc1782.
7. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogenesis and anticancer immune responses. Nat Immunol (2012) 13:343-51. doi:10.1038/ni.2224.
8. Drexler SK, Yazdi AS. Complex roles of inflammasomes in carcinogenesis. Cancer J (2013) 19:468-72. doi:10.1097/PPO.0000000000000004.
9. Kolb R, Liu GH, Janowski AM, Sutterwala FS, Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell (2014) 5:12-20. doi:10.1007/s13238-013-0001-4.
10. Ye Z, Ting JP. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol (2008) 20:3-9. doi:10.1016/j.coi.2008.01.003.
11. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, et al. The NLR gene family: a standard nomenclature. Immunity (2008) 28:285-7. doi:10.1016/j.immuni.2008.02.005.
12. Nunes T, de Souza HS. Inflammasome in intestinal inflammation and cancer. Mediators Inflamm (2013) 2013:654963. doi:10.1155/2013/654963.
13. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol (2004) 22:329-60. doi:10.1146/annurev.immunol.22.012703.104803.
14. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet (2001) 357:539-45. doi:10.1016/S0140-6736(00)04046-0.
15. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J Carcinog (2011) 10:9. doi:10.4103/1477-3163.78279.
16. Normand S, Delanoye-Crespin A, Bressenot A, Huot L, Grandjean T, Peyrin-Biroulet L, et al. NOD-like receptor pyrin domain-containing protein 6 (NLRP6) controls epithelial self-renewal and colorectal carcinogenesis upon injury. Proc Natl Acad Sci U S A (2011) 108:9601-6. doi:10.1073/pnas.1100981108.
17. Elinav E, Strowig T, Kau AL, Henao-Mejia J, Thaiss CA, Booth CJ, et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell (2011) 145:745-57. doi:10.1016/j.cell.2011.04.022.
18. Zaki MH, Vogel P, Body-Malapel M, Lamkanfi M, Kanneganti TD. IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation. J Immunol (2010) 185:4912-20. doi:10.4049/jimmunol.1002046.
19. Allen IC, Tekippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med (2010) 207:1045-56. doi:10.1084/jem.20100050.
20. Hu B, Elinav E, Flavell RA. Inflammasome-mediated suppression of inflammation-induced colorectal cancer progression is mediated by direct regulation of epithelial cell proliferation. Cell Cycle (2011) 10:1936-9. doi:10.4161/cc.10.12.16008.
21. Werts C, Rubino S, Ling A, Girardin SE, Philpott DJ. NOD-like receptors in intestinal homeostasis, inflammation, and cancer. J Leukoc Biol (2011) 90:471-82. doi:10.1189/jlb.0411183.
22. Zaki MH, Lamkanfi M, Kanneganti TD. The Nlrp3 inflammasome: contributions to intestinal homeostasis. Trends Immunol (2011) 32:171-9. doi:10.1016/j.it.2011.02.002.
23. Zaki MH, Vogel P, Malireddi RK, Body-Malapel M, Anand PK, Bertin J, et al. The NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis. Cancer Cell (2011) 20:649-60. doi:10.1016/j.ccr.2011.10.022.
24. Allen IC, Wilson JE, Schneider M, Lich JD, Roberts RA, Arthur JC, et al. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity (2012) 36:742-54. doi:10.1016/j.immuni.2012.03.012.
25. Dupaul-Chicoine J, Yeretssian G, Doiron K, Bergstrom KS, McIntire CR, Leblanc PM, et al. Control of intestinal homeostasis, colitis, and colitis-associated colorectal cancer by the inflammatory caspases. Immunity (2010) 32:367-78. doi:10.1016/j.immuni.2010.02.012.
26. Negash AA, Ramos HJ, Crochet N, Lau DT, Doehle B, Papic N, et al. IL-1beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease. PLoS Pathog (2013) 9:e1003330. doi:10.1371/journal.ppat.1003330.
27. Watanabe A, Sohail MA, Gomes DA, Hashmi A, Nagata J, Sutterwala FS, et al. Inflammasome-mediated regulation of hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol (2009) 296:G1248-57. doi:10.1152/ajpgi.90223.2008.
28. Dunn JH, Ellis LZ, Fujita M. Inflammasomes as molecular mediators of inflammation and cancer: potential role in melanoma. Cancer Lett (2012) 314:24-33. doi:10.1016/j.canlet.2011.10.001.
29. Reed JR, Leon RP, Hall MK, Schwertfeger KL. Interleukin-1beta and fibroblast growth factor receptor 1 cooperate to induce cyclooxygenase-2 during early mammary tumorigenesis. Breast Cancer Res (2009) 11:R21. doi:10.1186/bcr2246.
30. Tu S, Bhagat G, Cui G, Takaishi S, Kurt-Jones EA, Rickman B, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell (2008) 14:408-19. doi:10.1016/j.ccr.2008.10.011.
31. Drexler SK, Bonsignore L, Masin M, Tardivel A, Jackstadt R, Hermeking H, et al. Tissue-specific opposing functions of the inflammasome adaptor ASC in the regulation of epithelial skin carcinogenesis. Proc Natl Acad Sci U S A (2012) 109:18384-9. doi:10.1073/pnas.1209171109.
32. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 3:991-8. doi:10.1038/ni1102-991.
33. Smyth MJ, Thia KY, Street SE, Macgregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med (2000) 192:755-60. doi:10.1084/jem.192.5.755.
34. Street SE, Hayakawa Y, Zhan Y, Lew AM, Macgregor D, Jamieson AM, et al. Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med (2004) 199:879-84. doi:10.1084/jem.20031981.
35. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol (2007) 19:203-8. doi:10.1016/j.coi.2007.02.001.
36. Croxford JL, Tang ML, Pan MF, Huang CW, Kamran N, Phua CM, et al. ATM-dependent spontaneous regression of early Emu-myc-induced murine B-cell leukemia depends on natural killer and T cells. Blood (2013) 121:2512-21. doi:10.1182/blood-2012-08-449025.
37. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 15:1170-8. doi:10.1038/nm.2028.
38. Asano K, Nabeyama A, Miyake Y, Qiu CH, Kurita A, Tomura M, et al. CD169-positive macrophages dominate antitumor immunity by crosspresenting dead cell-associated antigens. Immunity (2011) 34:85-95. doi:10.1016/j.immuni.2010.12.011.
39. Huang TT, Ojcius DM, Young JD, Wu YH, Ko YF, Wong TY, et al. The anti-tumorigenic mushroom Agaricus blazei Murill enhances IL-1beta production and activates the NLRP3 inflammasome in human macrophages. PLoS One (2012) 7:e41383. doi:10.1371/journal.pone.0041383.
40. Garaude J, Kent A, Van Rooijen N, Blander JM. Simultaneous targeting of toll- and NOD-like receptors induces effective tumor-specific immune responses. Sci Transl Med (2012) 4:120ra116. doi:10.1126/scitranslmed.3002868.
41. Kikuchi T, Akasaki Y, Joki T, Abe T, Kurimoto M, Ohno T. Antitumor activity of interleukin-18 on mouse glioma cells. J Immunother (2000) 23:184-9. doi:10.1097/00002371-200003000-00002.
42. Hashimoto W, Tanaka F, Robbins PD, Taniguchi M, Okamura H, Lotze MT, et al. Natural killer, but not natural killer T, cells play a necessary role in the promotion of an innate antitumor response induced by IL-18. Int J Cancer (2003) 103:508-13. doi:10.1002/ijc.10844.
43. Nishio S, Yamada N, Ohyama H, Yamanegi K, Nakasho K, Hata M, et al. Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18. Cancer Sci (2008) 99:113-20. doi:10.1111/j.1349-7006.2007.00636.x.
44. Zheng JN, Pei DS, Mao LJ, Liu XY, Sun FH, Zhang BF, et al. Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis. Cancer Gene Ther (2010) 17:28-36. doi:10.1038/cgt.2009.38.
45. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 84:988-93. doi:10.1189/jlb.1107774.
46. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:646-74. doi:10.1016/j.cell.2011.02.013.
47. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med (1986) 315:1650-9. doi:10.1056/NEJM198612253152606.
48. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol (2008) 9:628-38. doi:10.1038/nrm2455.
49. Tyler DS, Francis GM, Frederick M, Tran AH, Ordonez NG, Smith JL, et al. Interleukin-1 production in tumor cells of human melanoma surgical specimens. J Interferon Cytokine Res (1995) 15:331-40. doi:10.1089/jir.1995.15.331.
50. Elaraj DM, Weinreich DM, Varghese S, Puhlmann M, Hewitt SM, Carroll NM, et al. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res (2006) 12:1088-96. doi:10.1158/1078-0432.CCR-05-1603.
51. Okamoto M, Liu W, Luo Y, Tanaka A, Cai X, Norris DA, et al. Constitutively active inflammasome in human melanoma cells mediating autoinflammation via caspase-1 processing and secretion of interleukin-1 beta. J Biol Chem (2010) 285:6477-88. doi:10.1074/jbc.M109.064907.
52. Knowles H, Leek R, Harris AL. Macrophage infiltration and angiogenesis in human malignancy. Novartis Found Symp (2004) 256:189-200. doi:10.1002/0470856734.ch14.
53. Vidal-Vanaclocha F, Fantuzzi G, Mendoza L, Fuentes AM, Anasagasti MJ, Martin J, et al. IL-18 regulates IL-1beta-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1. Proc Natl Acad Sci U S A (2000) 97:734-9. doi:10.1073/pnas.97.2.734.
54. Cho D, Song H, Kim YM, Houh D, Hur DY, Park H, et al. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res (2000) 60:2703-9.
55. Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res (2011) 71:5393-9. doi:10.1158/0008-5472.CAN-11-0993.
56. van Deventer HW, Burgents JE, Wu QP, Woodford RM, Brickey WJ, Allen IC, et al. The inflammasome component NLRP3 impairs antitumor vaccine by enhancing the accumulation of tumor-associated myeloid-derived suppressor cells. Cancer Res (2010) 70:10161-9. doi:10.1158/0008-5472.CAN-10-1921.
57. Bruchard M, Mignot G, Derangere V, Chalmin F, Chevriaux A, Vegran F, et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat Med (2013) 19:57-64. doi:10.1038/nm.2999.